53
Participants
Start Date
December 31, 2014
Primary Completion Date
February 29, 2016
Study Completion Date
February 29, 2016
ALX-0171
Placebo
Investigator Site 1, Budapest
Investigators Site 3, Budapest
Investigator Site 2, Randwick
Investigator Site 1, Westmead
Investigator Site 2, Szeged
Investigator Site 1, Santiago de Compostela
Investigator Site 4, Girona
Investigator Site 3, Madrid
Investigator Site 3, Bratislava
Investigator Site 5, Banská Bystrica
Investigator Site 4, Brisbane
Investigator Site 3, Tasmania
Investigator Site 1, Antwerp
Investigator Site 6, Antwerp
Investigator Site 4, Brussels
Investigator Site 5, Brussels
Investigator Site 2, Ghent
Investigator Site 3, Leuven
Investigator Site 4, Kozloduy
Investigator Site 1, Pleven
Investigator Site 2, Rousse
Investigator Site 3, Sevlievo
Investigator Site, Tartu
Investigator Site 4, Budapest
Investigator Site 5, Budapest
Investigator Site 3, Beersheba
Investigator Site 2, Haifa
Investigator Site 1, Petah Tikva
Investigator Site 3, Daugavpils
Investigator Site 2, Riga
Investigator Site 1, Valmiera
Investigator Site 2, Ipoh
Investigator Site 1, Kuala Lumpur
Investigator Site 3, Negeri Sembilan
Investigator Site 4, Pulau Pinang
Investigator Site, City of Muntinlupa
Investigator Site, Manila
Investigator Site, Quezon City
Investigator Site 3, Bydgoszcz
Investigator Site 2, Lodz
Investigator Site 1, Trzebnica
Investigator Site 6, Levice
Investigator Site 7, Liptovský Mikuláš
Investigator Site 7, Málaga
Investigator Site 6, Murcia
Investigator Site 8, Seville
Investigator Site 2, Chiang Mai
Investigator Site, Khon Kaen
Investigator Site 2, City of Edinburgh
Investigator Site 4, Kent
Investigator Site 5, Liverpool
Investigator Site 6, Nottingham
Investigator Site 1, Oxford
Investigator Site 3, Tooting
Investigator Site 2, Košice
Investigator Site 1, Martin
Investigator Site 4, Poprad
Investigator Site 5, Barcelona
Investigator Site 2, Barcelona
Ablynx, a Sanofi company
INDUSTRY